CHATSWORTH, Calif., April 4, 2011 (GLOBE NEWSWIRE) -- IRIS INTERNATIONAL, INC. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables, and a provider of high value personalized diagnostics testing services through its CLIA certified molecular diagnostics laboratory, announced today that it has entered into a Joint Development Agreement with Fujirebio Inc., one of the largest in vitro diagnostics companies in Japan, for the co-development of the IRIS 3GEMS™ Hematology Analyzer product line.
